Slide 1: Results Presentation for the Half-year ended 31 December 2023
For immediate release 13 February 2024 Results Presentation for the Half-year ended 31 December 2023 Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the slides for the presentation on the half year results that will be given by the Chief Executive Officer and the Chief Financi
Slide 2: CSL Limited 2024 Half Year Results
CSL Limited 2024 Half Year Results 13 February 2024 Paul McKenzie Joy Linton CEO & Managing Director CFO
Slide 3: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be comple
Slide 4: CEO Overview
01 CEO Overview Paul McKenzie CEO & Managing Director 3
Slide 5: Strong performance
Strong performance1 Revenue +11%, NPATA2,3 +13%, NPAT +20% CSL Behring Revenue CSL Seqirus by Segment Solid performance in a Strong growth across the challenging season portfolio especially Ig • FLUAD® +14% • Ig +23%, KCENTRA® +12%, • Regulatory approval for world first sa-mRNA HAEGARDA® +9% COVID v
Slide 6: CSL Behring revenue up 14%
Revenue up 14%1 Revenue Change1 Major Therapy $m % Performance Brands • Strong growth across all geographies Ig – PRIVIGEN® / INTRAGAM® +27%, HIZENTRA +18% 2,757 23% • Significant patient demand in core indications • HIZENTRA® 50ml pre-filled syringe launch in the US • Strong growth in emerging mark
Slide 7: Plasma Highlights
Plasma Highlights • Underlying fundamentals of plasma collection remain strong Benefits of RIKA Plasma Donation System • 10% reduction in CPL1 • Expanding geographic footprint of plasma collection • Fewer donor deferrals; reduced donation network time by ~30% • RIKA • Individualised Nomogram will im
Slide 8: Current Season Dynamics
Current Season Dynamics Revenue up 2%1 • Reduced rates of immunisation • Competitive price pressures • Overburdened healthcare system Revenue $m Change1 % Performance Major Brands Egg Based 123 0% • Revenue growth in the northern hemisphere influenza market in a challenging season • Heightened recog
Slide 9: Operational Highlights
Operational Highlights Seasonal influenza Product Innovation Pandemic influenza products • FLUCELVAX® 6-month+ age • Phase III clinical study • UK Advance Purchase Agreement extension approved in UK, commenced for aQIVc awarded solely to CSL Seqirus Australia and New Zealand • Regulatory approval fo
Slide 10: Nephrology
Revenue1 $m Major Brands Highlights • China FERINJECT® inclusion in the National Reimbursement Drug List Iron 505 • Well prepared for a transitioning iron market • US step edit pressure • MIRCERA® • Strong ESA performance in the U.S., as patients 2 convert • KAPRUVIA® • Approved in multiple emerging
Slide 11: Pipeline
02 Pipeline Bill Mezzanotte EVP & Head of R&D 10
Slide 12: CSL112 Apolipoprotein A-I (human) - AEGIS-II
CSL112 Apolipoprotein A-I (human) - AEGIS-II Objective: to evaluate the efficacy and safety of CSL112 on reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), or stroke Treatment period Follow-up period (1 year) (4 weekly infusions) 6 g CSL112 (n=9,112) 18,219 MI patients from
Slide 13: CSL112 Apolipoprotein A-I (human) - AEGIS-II
CSL112 Apolipoprotein A-I (human) - AEGIS-II Objective: to evaluate the efficacy and safety of CSL112 on reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), or stroke • For the primary efficacy endpoint at 90 days, the trial did not meet the threshold for statistical signific
Slide 14: Recent Late-Phase R&D Highlights
Recent Late-Phase R&D Highlights • Clazakizumab for reduction of cardiovascular events in patients with End-Stage Kidney Disease (ESKD) • Well-characterized link of inflammation and cardiovascular morbidity and mortality in patients with ESKD • Positive phase 2b data; Phase 3 prepared to start 2Q 20
Slide 15: Financials
03 Financials Joy Linton CFO 14
Slide 16: NPATA
NPATA1 1H23 1H24 Rep @ CC3 $2,056m FX $39m NPATA $1,818m2 $2,056m2 Acquired intangible assets ($88m) ($129m) amortisation One-off acquisition adjustments ($184m) ($49m) Tax $35m $31m4 $2,017m NPATA Attributable to NCI5 $59m $53m $1,818m NPAT $1,640m $1,962m NPAT Attributable to NCI5 ($17m) ($20m) NP
Slide 17: CSL Group Financial Highlights
CSL Group Financial Highlights 1H23 1H24 1H24 Change 1 1 US$ Millions Rep Rep at CC % R&D Total Revenue 7,184 8,053 7,954 11% Growth in line with sales Gross Profit3 4,042 4,494 4,491 11% Anticipate FY24 within 10-11% of revenue GP %3 56.3% 55.8% 56.5% G&A Sales & Marketing 683 707 696 2% Favourable
Slide 18: CSL Group 1H24 by Segment
CSL Group 1H24 by Segment CSL CSL CSL CSL Change 1 US$ millions reported Behring Seqirus Vifor Group % at CC Sales 5,093 1,705 1,006 7,804 11% Other Revenue 145 99 5 249 2% Total Revenue 5,238 1,804 1,011 8,053 11% Gross Profit2 2,617 1,207 670 4,494 11% Reported GP %2 50.0% 66.9% 66.3% 55.8% Sales
Slide 19: CEO Overview
04 CEO Overview Paul McKenzie CEO & Managing Director 18
Slide 20: Outlook
Outlook1 CSL Behring CSL Seqirus CSL Vifor • Underlying patient • Progression of • Well positioned for iron demand for Ig in core global registrations competition indications remain for next- • Nephrology launch strong generation mRNA momentum • 2H growth expected COVID vaccine FY24 Guidance • Unloc
Slide 21: CSL Contacts
CSL Contacts Mark Dehring VP Investor Relations +61 3 9389 3407 mark.dehring@csl.com.au Bernard Ronchi Investor Relations +61 3 9389 3470 bernard.ronchi@csl.com.au Stephen McKeon Investor Relations +61 3 9389 6798 stephen.mckeon@csl.com.au
Slide 22: Notes
Notes (#) Constant currency removes the impact of exchange Summary NPAT attributable to members rate movements to facilitate comparability of operational of parent entity performance for the Group. This is done in three parts: a) Reported net profit after tax $1,901m by converting the current year n
Slide 23: Appendix
Appendix 22
Slide 24: Appendix A: CSL Behring Key Products
Appendix A CSL Behring – Key Products CSL BEHRING Therapy Group Sales $m Change1 % HY24 Revenue By Therapy Group $m Privigen IVIG 1,768 35% 9% 4%, Other Other, Hizentra SCIG 945 18% $242 Specialty $450 Albumin Albumin 613 8% 10%, 35% Peri-Operative IVIG Idelvion Haemophilia 390 7% Bleeding, $1,812 $
Slide 25: Appendix B: CSL Vifor & CSL Seqirus Key Products
Appendix B CSL Vifor & CSL Seqirus – Key Products HY24 Revenue By Therapy Group $m 5%, Pandemic, $85 0% Other Income $14 4%, In License, $65 29%, CSL SEQIRUS Therapy Group Sales $m Change1 % Cell Culture, 7%, Egg Based, Fluad Adjuvanted 988 14% $123 $529 Flucelvax Cell culture 529 (13%) Afluria Egg-